Research programme: stroke therapy - ChemokineAlternative Names: CTCE-0501
Latest Information Update: 24 Jul 2007
At a glance
- Originator Chemokine Therapeutics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Stroke
Most Recent Events
- 24 Jul 2007 Preclinical development is ongoing
- 08 Mar 2006 Preclinical trials in Stroke in Canada (unspecified route)